AU2021321536A1 - Kinase inhibitors and uses thereof - Google Patents

Kinase inhibitors and uses thereof Download PDF

Info

Publication number
AU2021321536A1
AU2021321536A1 AU2021321536A AU2021321536A AU2021321536A1 AU 2021321536 A1 AU2021321536 A1 AU 2021321536A1 AU 2021321536 A AU2021321536 A AU 2021321536A AU 2021321536 A AU2021321536 A AU 2021321536A AU 2021321536 A1 AU2021321536 A1 AU 2021321536A1
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
compound
pyrido
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021321536A
Other languages
English (en)
Inventor
Chen Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abm Therapeutics Corp
Original Assignee
Abm Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abm Therapeutics Corp filed Critical Abm Therapeutics Corp
Publication of AU2021321536A1 publication Critical patent/AU2021321536A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021321536A 2020-08-07 2021-08-06 Kinase inhibitors and uses thereof Pending AU2021321536A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063063113P 2020-08-07 2020-08-07
US63/063,113 2020-08-07
PCT/US2021/044907 WO2022032071A1 (en) 2020-08-07 2021-08-06 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
AU2021321536A1 true AU2021321536A1 (en) 2023-03-09

Family

ID=77711412

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021321536A Pending AU2021321536A1 (en) 2020-08-07 2021-08-06 Kinase inhibitors and uses thereof

Country Status (10)

Country Link
US (1) US20230303570A1 (https=)
EP (1) EP4192582A1 (https=)
JP (1) JP2023538521A (https=)
KR (1) KR20230112605A (https=)
CN (1) CN116710453A (https=)
AU (1) AU2021321536A1 (https=)
BR (1) BR112023002248A2 (https=)
CA (1) CA3179671A1 (https=)
MX (1) MX2023001312A (https=)
WO (1) WO2022032071A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4577546A1 (en) * 2022-08-25 2025-07-02 Enliven Inc. Naphthyridine compounds for inhibition of raf kinases
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2025064567A1 (en) * 2023-09-19 2025-03-27 Enliven Inc. Tricyclic phenols for inhibition of raf kinases
WO2025152919A1 (en) * 2024-01-15 2025-07-24 Impact Therapeutics (Shanghai) , Inc. Crystal forms of a weel inhibitor and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503802A (ja) * 2002-04-03 2006-02-02 エフ．ホフマン−ラ　ロシュ　アーゲー イミダゾ縮合化合物
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
FR2974088A1 (fr) * 2011-04-12 2012-10-19 Pf Medicament Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
RU2019102647A (ru) * 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
CN110950867A (zh) * 2018-09-27 2020-04-03 首药控股(北京)有限公司 一种fgfr4激酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
CA3179671A1 (en) 2022-02-10
KR20230112605A (ko) 2023-07-27
EP4192582A1 (en) 2023-06-14
JP2023538521A (ja) 2023-09-08
CN116710453A (zh) 2023-09-05
WO2022032071A1 (en) 2022-02-10
MX2023001312A (es) 2023-04-12
US20230303570A1 (en) 2023-09-28
BR112023002248A2 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
AU2022349569A1 (en) Pyridine derivative and use thereof
AU2018222943B2 (en) Heterocyclic compounds useful as PDK1 inhibitors
KR102609431B1 (ko) Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체
EP3152210B1 (en) Tank-binding kinase inhibitor compounds
EP2558468B1 (en) 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
EP2855459B1 (en) Aminoquinazoline and pyridopyrimidine derivatives
AU2021321536A1 (en) Kinase inhibitors and uses thereof
JP2020525522A (ja) Ｒｈｏ−関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
EP3952870A1 (en) Phosphatidylinositol 3-kinase inhibitors
CA3107365A1 (en) Pyrazine compounds and uses thereof
EP2951169A1 (en) Flap modulators
EP3070085B1 (en) Flap modulators
CN112457326B (zh) 一类芳香杂环并内酰胺类化合物、制备方法和用途
JP2023513333A (ja) キノリニル基ホスフィンオキシド化合物、並びにその組成物及び使用
TW202204351A (zh) 具有大環結構的化合物及其用途
WO2023139085A1 (en) New benzimidazole pyridine derivatives
WO2024015497A1 (en) Tyrosine kinase 2 inhibitors and uses thereof
AU2024353744A1 (en) Triazolopyridinyl compounds as kinase inhibitors
WO2025072395A1 (en) Triazolopyridinyl compounds as kinase inhibitors
HK40100224A (zh) 激酶抑制剂及其用途
HK1231042B (en) Flap modulators
HK1231042A1 (en) Flap modulators
HK1249512B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
EA045220B1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK1236197B (en) Tank-binding kinase inhibitor compounds